Drug
Peginterferon Beta 1A
Peginterferon Beta 1A: highest development phase Post-Market, developed by Biogen. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Biogen
Trials
| Drug | Phase | Indication |
|---|---|---|
| peginterferon beta-1a NCT03177083 | Post-Market | Relapsing Remitting Multiple Sclerosis |
| peginterferon beta-1a NCT02587065 | Post-Market | Relapsing-Remitting Multiple Sclerosis (RRMS) |
| Peginterferon Beta-1a NCT01978652 | Phase 1 | Healthy |
Latest
No recent events.
Follow Peginterferon Beta 1A on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.